帕罗西汀对比度洛西汀治疗抑郁症的系统评价及药物经济学分析

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (1165 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To provide evidence-based evidence for the choice of drugs for clinical treatment of depression and to evaluate the economics. Methods CNKI, WanFang, VIP, PubMed, EMBase, Cochrane library and SinoMed were all searched. Randomized controlled trials of Paroxetine and Duloxetine in the treatment of depression were screened, the retrieval time was set up until March 2020. Meta-analysis and pharmacoeconomic analysis were performed using RevMan 5.3 software and cost-effectiveness ratio. Results A total of 12 RCT articles, 1722 patients were included in the analysis. Meta-analysis results showed that there was no significant difference in the total effective rate between the two groups in treating depression (RR = 1.01, 95%CI [0.96, 1.07], P = 0.65), after treatment, there was a statistically significant difference in the score of hamilton depression scale between the two groups (MD = 0.71, 95%CI [0.25, 1.17], P = 0.003), and there was a statistically significant difference in the adverse reactions between the two groups (RR = 1.11, 95%CI [1.01, 1.21], P = 0.02), and both groups were well tolerated. In terms of pharmacoeconomics, the cost-effectiveness ratio of paroxetine was 371.21 and the duloxetine was 536.11, incremental cost-effectiveness ratio was -28 431.03. Conclusion Paroxetine and Duloxetine have similar clinical effects in the treatment of depression, and paroxetine is more prone to adverse reactions, and paroxetine has economic advantages.

Key words： Paroxetine Duloxetine Depression Efficacy Safety Drug economy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Xing WANG Xiaoli

Cite this article:

CHEN Xing WANG Xiaoli. Systematic evaluation and pharmacoeconomic analysis of Paroxetine versus Duloxetine in treatment of depression[J]. 中国医药导报, 2021, 18(9): 140-144.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2021/V18/I9/140

[1] 江开达.精神病学[M].北京：人民卫生出版社，2005：123-124.
[2] Amanuel AA，Kalkidan HA，Cristiana A，et al. Global，regional，and national under-5 mortality，adult mortality，age-specific mortality，and life expectancy，1970-2016：a systematic analysis for the Global Burden of Disease Study 2016 [J]. Lancet，2017，390（10100）：1084-1150.
[3] 邹万芹.新型抗抑郁药的临床应用及研究进展[J].中国药房，2008，19（14）：1105-1107.
[4] Gueorguieva R，Mallinckrodt C，Krystal JH. Trajectories of depression severity in clinical trials of duloxetine：insights into antidepressant and placebo responses [J]. Arch Gen Psychiatry，2011，68（12）：1227-1237.
[5] 汪凯，朱春燕，陈海波.综合医院焦虑，抑郁与躯体化症状诊断治疗的专家共识[J].中华神经科杂志，2016，49（12）：908-917.
[6] 樊伊楠，姜文海，赵希武，等.行为认知治疗技术对抑郁焦虑患者的长期疗效分析[J].中国医药导报，2015，12（10）：67-70.
[7] 马捷，刘莹，钟来平，等.Jadad量表与Cochrane偏倚风险评估工具在随机对照试验质量评价中的应用与比较[J].中国口腔颌面外科杂志，2012，10（5）：417-422.
[8] 刘艳萍，陈泳康，刘梅.度洛西汀与帕罗西汀治疗120例抑郁症患者的临床疗效[J].中国药物经济学，2015，10（8）：57-58.
[9] 陈进东.度洛西汀与帕罗西汀治疗伴躯体症状抑郁症的对照研究[A].中国中西医结合学会精神疾病专业委员会.第十三届全国中西医结合精神疾病学术会议论文集[C].中国中西医结合学会精神疾病专业委员会：中国中西医结合学会，2014：4.
[10] 杨荣.度洛西汀与帕罗西汀治疗抑郁症的对照研究[J].中国处方药，2014，12（5）：54.
[11] 陈朝晖.度洛西汀与帕罗西汀治疗抑郁症的疗效与安全性对比观察[J].中国社区医师，2017，33（19）：27-28.
[12] 王东明，刘琳琳.老年抑郁症应用度洛西汀与帕罗西汀治疗的效果对照评析[J].中国医药指南，2017，15（16）：34-35.
[13] 万俊玲.度洛西汀与帕罗西汀治疗老年抑郁症的对照研究[J].中国民康医学，2014，26（16）：27-29.
[14] 王传文，张晓东.度洛西汀与帕罗西汀治疗抑郁症的疗效比较[J].中国药物经济学，2014，9（S1）：155-156.
[15] Wang ZY，Xu XF，Tan QR. Treatment of major depressive disorders with generic duloxetine and paroxetine：a multi-centered，double-blind，double-dummy，randomized controlled clinical trial [J]. Shanghai Arch Psychiatry，2015，27（4）：228-236.
[16] Lee P，Shu L，Xu X，et al. Once-daily duloxetine 60 mg in the treatment of major depressive disorder：multicenter，double-blind，randomized，paroxetine-controlled，non-inferiority trial in China，Korea，Taiwan and Brazil [J]. Psychiatry Clin Neurosci，2007，61（3）：295-307.
[17] Perahia DG，Wang F，Mallinckrodt CH. Duloxetine in the treatment of major depressive disorder：a placebo- and paroxetine-controlled trial [J]. Eur Psychiatry，2006，21（6）：367-378.
[18] 高宏强，尤加永，顾广善.度洛西汀与帕罗西汀治疗抑郁症的对照研究[J].临床合理用药杂志，2011，4（24）：7-8.
[19] 安彦敏，时立妲，丛晓山，等.度洛西汀与帕罗西汀治疗抑郁症的对照研究[J].河北医药，2011，33（19）：2922-2923.
[20] 管欣，李洪超，姚嘉奇，等.药物经济学评价中Meta分析结果应用方法的比较与选择[J].中国循证医学杂志，2018，18（11）：1224-1231.
[21] 顾海，李洪超.药物经济学成本-效果分析应用的相关问题探讨[J].中国药房，2004，15（11）：34-36.
[22] 祁鑫川，宋金鹏.盐酸帕罗西汀治疗抑郁症的效果及对患者生活事件、防御方式及不良反应的影响[J].临床医学研究与实践，2019，4（22）：62-64.
[23] 江开达，李凌江，王刚.度洛西汀治疗抑郁症及广泛性焦虑障碍临床应用指导建议[J].中国新药与临床杂志，2012，31（9）：520-536.
[24] 《中国药物经济学评价指南》课题组.中国药物经济学评价指南（2011版）[J].中国药物经济学，2011（3）：6-9， 11-48.
[25] 国家统计局.中国统计年鉴2019[DB/OL].http：//www.stats.gov.cn/tjsj/ndsj/2019/indexch.htm.